sodium tungstate(vi) has been researched along with Diabetic Nephropathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertinat, R; Gatica, R; Gomis, R; Nualart, F; Oliveira, JM; Silva, P; Westermeier, F; Yáñez, AJ | 1 |
| Bertinat, R; Li, X; Mann, E; Nualart, F; Silva, P; Yáñez, AJ | 1 |
2 other study(ies) available for sodium tungstate(vi) and Diabetic Nephropathies
| Article | Year |
|---|---|
The Antidiabetic Agent Sodium Tungstate Induces Abnormal Glycogen Accumulation in Renal Proximal Tubules from Diabetic IRS2-Knockout Mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycogen; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Kidney; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphoenolpyruvate Carboxykinase (ATP); Signal Transduction; Tungsten Compounds | 2018 |
In vivo sodium tungstate treatment prevents E-cadherin loss induced by diabetic serum in HK-2 cell line.
Topics: Animals; Cadherins; Cell Differentiation; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial Cells; Humans; Rats, Sprague-Dawley; Tungsten Compounds; Vascular Endothelial Growth Factor A | 2015 |